Psoriasis Vulgaris with or without Arthritis and Independent of Disease Severity or Duration Is a Risk Factor for Hypercholesterolemia

Abstract

Background: Psoriasis (Ps) has been associated with an increased incidence of cardiovascular disease. Interesting epidemiological evidence suggests associations between Ps and dyslipidemia (DL), a well-established risk factor for cardiovascular disease. Objective: This study aimed to investigate the association between Ps and multiple measurements of DL, which include levels of triglycerides (TGs), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and total cholesterol (TCh). We also studied the relationship between DL and disease duration. Methods: A prospective hospital-based study was conducted. A total of 661 Caucasian patients with chronic plaque Ps and 661 sex- and age-matched controls were enrolled. Results: Multivariate analysis showed that in psoriatic patients the odds ratio (OR) of TCh >200 mg/dl was 1.406 (95% confidence interval 1.115-1.173), the OR of LDL cholesterol >130 mg/dl was 1.375 (95% confidence interval 1.088-1.738), the OR of HDL cholesterol <40 mg/dl was 0.881 (95% confidence interval 0.599-1.297), and the OR of TGs >150 mg/dl was 1.041 (95% confidence interval 0.783-1.385). We did not find a relationship between lipid levels and disease duration. Conclusion: Based on our population Ps is associated with alterations in TCh and LDL cholesterol, but not in TGs and HDL cholesterol, when ATP III panel levels are used. These alterations are not related to disease duration.

Psoriasis as a Predictor of Cardiometabolic Comorbidity in Women: A Study Based on the Danish National Birth Cohort

“…In general, the results showed a unidirectional association between psoriasis and the comorbidities investigated. This supports the results of previous research on psoriasis and hypertension (11), ischaemic heart disease (3,12), T2D (11,13,14), and hypercholesterolaemia (15,16). Our results are also consistent with the hypothesis of there being an underlying common pathogenetic mechanism, such as the "psoriatic march", as described in the Introduction (5).…”

Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice

“…Our series features more patients with DM, arterial hypertension, dyslipidemia, and psoriatic arthritis than those of the BIOBADADERM [18], BADBIR [22], GALLUZO [27], and ELDERDIN [29] studies. We attribute these differences to the active search for these patients undertaken by the HUCA psoriasis clinic, which has already been widely reported in the literature [34][35][36][37].…”

The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus

“…This mostly stems from the association of psoriasis with lipid metabolism abnormalities underlying the atherosclerosis initiation and progression. Psoriasis has been shown to be associated with higher levels of LDL and triglycerides, and lower HDL levels [32]. Moreover, oxidised LDL is present in psoriatic epidermis, but not in healthy skin from psoriatic patients [33].…”